Recombinant CD276 (Ifinatamab Biosimilar) antibody

Catalog No. ABIN7795144

The Humanized Monoclonal anti-CD276 (Ifinatamab Biosimilar) antibody (ABIN7795144) specifically detects CD276 (Ifinatamab Biosimilar) in FACS and in vivo. The antibody is reactive with Human samples.

Quick Overview for Recombinant CD276 (Ifinatamab Biosimilar) antibody (ABIN7795144)

Target: CD276 (Ifinatamab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Humanized

Clonality: Monoclonal

Conjugate: This CD276 (Ifinatamab Biosimilar) antibody is un-conjugated

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Grade: Research Grade

Product Details anti-CD276 (Ifinatamab Biosimilar) Antibody

Expression System: Mammalian cells

Purpose: Ifinatamab Biosimilar, Human B7-H3 Monoclonal Antibody

Characteristics: What is ifinatamab biosimilar research grade? Ifinatamab is a humanized IgG1-kappa monoclonal antibody against the human B7-H3 (CD276) protein, a type I transmembrane protein belonging to the B7 family which includes immune checkpoint molecules CTLA-4 and PD-L1. B7-H3 is highly expressed in various types of solid tumors with low expression in normal (healthy) tissues. It was reported that B7-H3 overexpression is associated with poor prognosis in several types of cancers. Ifinatamab biosimilar uses the same protein sequences as the therapeutic antibody ifinatamab.

Purification: Protein A or G affinity column

Purity: >95 % by reducing SDS-PAGE

Endotoxin Level: < 1 EU per 1 mg of the protein by the LAL method

Immunogen: Human B7-H3

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: > 3 mg/mL

Storage: 4 °C,-20 °C

Storage Comment: Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.

Target Details for CD276 (Ifinatamab Biosimilar)

Target: CD276 (Ifinatamab Biosimilar)

Alternative Name: Ifinatamab Biosimilar

Target Type: Biosimilar